While the EVUSHELD outcome does indicate a stronger move to apply the institutionalised decision-making framework, the transition does pose a challenge for decision-makers who will need to ensure the consistent and equitable consideration of vaccines and therapies for COVID-19.
Outcome highlights the challenge of delivering consistent approach
October 17, 2022 Latest NewsBioPharmaNews of the DayComment
Latest Video
New Stories
-
An institution dominated by very clever people, but where is the wisdom?
August 14, 2026 - - Latest News -
A plain language version of these dreadful and useless documents
August 14, 2026 - - Latest News -
CUREator+ backs six Australian startups with $13.5 million to advance new health technologies
August 13, 2026 - - Australian Biotech -
Medicines Australia appoints former AbbVie executive to key leadership role
August 13, 2026 - - Latest News -
VVMF and Optosleep partner to advance Australian gene therapy for sleep apnoea
August 13, 2026 - - Latest News -
Survey exposes deep gaps in neurological care across Australia
August 13, 2026 - - Latest News -
Australia 'is not an island' on pricing and we cannot be so arrogant to expect free product
August 13, 2026 - - Latest News

